首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma
【24h】

Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma

机译:新型多模式超高效液相色谱-串联质谱测定人血浆中对映体羟基华法林和华法林

获取原文
获取原文并翻译 | 示例
       

摘要

Coumadin (R/S-warfarin) is a commonly prescribed anticoagulant for over ~20 million Americans. Although highly efficacious, positive clinical outcomes during warfarin therapy depend on maintaining a narrow therapeutic range for the drug. This goal is challenging due to large inter-individual variability in patient response, which has been attributed to diversity in drug metabolism. Warfarin is given as a racemic mixture and evidence suggest differences of R and S-warfarin in their therapeutic activities and metabolism. Previous investigation of warfarin metabolism has been hampered by the inability to quantify the individual enantiomers. To overcome this limitation a multi-mode LC-MS/MS method is reported. This strategy combines phenyl based reverse phase chromatography with chiral phase chromatography prior to quantitation by liquid chromatography tandem mass spectrometry. This approach was made possible through advances in UPLC technology producing narrow peaks suitable for transferring to a second column. The reported method separated individual R and S enantiomers of hydroxywarfarin and warfarin. All four possible isomers of 10-hydroxywarfarin were resolved to reveal unprecedented insights into the stereo-specific metabolism of warfarin. Characterization of the method demonstrated that it is robust and sensitive with inter-day coefficients of error between <7% and a detection limit of 2. nM in sample or 10. fmol on column for each analyte. Individual metabolites may be suitable surrogate biomarkers or predictive markers that predict warfarin dose, adverse interactions, or other important clinical outcomes during anticoagulant therapy. Consequently, the metabolite profiles obtained through this dual phase UPLC-MS/MS method are expected to increase our understanding of the role warfarin metabolism plays in patient response to therapy and yield new strategies to improve patient outcomes.
机译:香豆素(R / S-华法林)是约2000万美国人常用的抗凝剂。尽管高效,华法林治疗期间的积极临床结果取决于维持药物的狭窄治疗范围。由于患者反应之间存在很大的个体差异,因此该目标具有挑战性,这归因于药物代谢的多样性。华法林以外消旋混合物形式存在,证据表明R和S-华法林的治疗活性和代谢存在差异。华法林代谢的先前研究因无法定量单个对映体而受阻。为了克服该限制,报道了一种多模式LC-MS / MS方法。在通过液相色谱串联质谱法进行定量之前,该策略将基于苯基的反相色谱与手性色谱相结合。通过UPLC技术的进步,产生了适合转移到第二根色谱柱的窄峰,使这种方法成为可能。报道的方法分离了羟基华法林和华法林的R和S对映体。解析了10-羟基华法林的所有四种可能的异构体,以揭示对华法林的立体特异性代谢的空前洞察。该方法的表征表明,该方法是稳健且灵敏的,日间误差系数在7%以下,并且每种分析物的样品的检出限为2. nM或柱上的10. fmol。个别代谢物可能是合适的替代生物标志物或预测标志物,可在抗凝治疗期间预测华法林剂量,不良相互作用或其他重要的临床结果。因此,通过这种双阶段UPLC-MS / MS方法获得的代谢物谱有望增强我们对华法林代谢在患者对治疗反应中的作用的了解,并产生改善患者预后的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号